GSK extends share buyback activity, shares supported by solid analyst consensus

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 23:13.

GSK (GB0009252882) has reported further progress in its ongoing share buyback, with recent repurchases disclosed in the latest filings for its New York listing on the NYSE.Recent SEC filing summary The program activity comes as the stock trades in London and New York against a relatively cautious analyst valuation backdrop.

What the filings show

According to a June 23, 2026 Form 6-K summary, GSK reported additional buyback activity executed between June 8 and June 12, 2026, via Citigroup Global Markets on UK exchanges at prices in the high-1,800 to low-2,000 pence range per ordinary share.Form 6-K recap of repurchases Since May 11, 2026, the company has repurchased 7,346,236 ordinary shares of 31.25 pence each into treasury.

After these transactions, GSK holds 268,724,522 ordinary shares in treasury, leaving 4,047,527,077 ordinary shares in issue excluding treasury and an equivalent number of voting rights outstanding.Voting rights and treasury share data Treasury shares now account for about 6.64 percent of total voting rights, which is relevant for investors monitoring UK transparency thresholds.

Analyst targets versus trading levels

On the London Stock Exchange, GSK shares recently traded in a daily range between 1,911 and 1,941.5 pence, implying a market capitalization of roughly £77.1 billion at a price-to-earnings ratio near 11.2.Hargreaves Lansdown price data The dividend yield stands around 3.4 percent based on a £0.18 per share payment with an ex-dividend date of February 19, 2026.

Consensus data compiled by a German market portal indicate that the average 12-month price target from 93 analysts sits near 18.0 pounds, below the current euro-equivalent level of about 22.85 euros for the Frankfurt-traded GSK line, suggesting limited upside from current quotations.Analyst consensus and performance overview Over one year, that same source reports a share price performance of roughly 36 percent, with the stock still trading about 14 percent under its 52-week high.

The business behind key products

GSK derives a significant share of its revenue from vaccines, with the shingles vaccine Shingrix a major growth driver in recent quarters, contributing to a quarterly sales figure of about $10.2 billion and an adjusted EPS of $1.25 that beat consensus estimates.Recent earnings highlights and product drivers Alongside Shingrix, GSK markets a broad portfolio of specialty and general medicines across respiratory, HIV, and immunology indications.

Where the stock trades today

The GSK shares (GB0009252882) most recently changed hands in London around 1,930 pence, while a parallel Frankfurt line was quoted near 22.85 euros as of 2026-06-23, 22:02, with the primary listing on the London Stock Exchange and an additional ADR on the NYSE.

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument.